智通财经APP讯，中基长寿科学(00767)公布，于2024年4月18日，公司的全资附属公司深圳市中基健康科学有限公司及公司间接非全资附属公司四川中基冠德生物科技有限公司与四川中农云起航数据科技集团有限公司订立合资协议，拟在中华人民共和国成立一间合资公司。合资公司于成立时将由中基冠德拥有51%、中基健康拥有25%及中农云拥有24%的股权。合资公司将主要从事在中国开发高血压、糖尿病临床管控新途径A+的微创技术、间质技术的应用，以及相关生物制品贸易的业务。 合资公司的初始注册资本为人民币200万元，将由中基冠德、中基健康及中农云按彼等各自于合资公司的权益比例出资。出资款将主要用作合资公司的营运资金。该集团将以其内部资源为其资本承担提供资金。 据悉，中农云是中华人民共和国农业农村部的全资附属公司蓝田投资总公司旗下的控股公司，注册资金为5000万元人民币，是多元化大型国有企业，业务范围涵盖：乡村振兴、林业碳汇、水利水电、应急领域、城市更新、文旅康养、医疗投资、产业投资等。 公告称，该集团主要透过其附属公司中基健康从事提供健康咨询及医疗产品贸易的业务，及中基冠德提供生物医药产品贸易的业务。董事会认为长寿生物制品及生物科 ...

Financial Performance - For the fiscal year ending December 31, 2023, the group's revenue decreased by 27.5% to HKD 65.0 million, compared to HKD 89.7 million in the fiscal year 2022[5]. - The group's gross profit for the fiscal year 2023 decreased by 32.9% to HKD 56.3 million, down from HKD 83.8 million in the previous year[5]. - The group's profit after tax increased by 259.9% to HKD 2.5 million for the fiscal year 2023, compared to HKD 0.7 million in fiscal year 2022[5]. - The total comprehensive loss for the fiscal year 2023 amounted to HKD 4.95 million, compared to a loss of HKD 69.61 million in fiscal year 2022[8]. - The adjusted profit before tax for the year ended December 31, 2023, was HKD 4,745,000, compared to HKD 9,323,000 in 2022, indicating a decrease of about 49.1%[22][24]. - The company reported a net profit of HKD 2,313,000 for 2023, compared to a net loss of HKD 904,000 in 2022[40]. - The annual profit for fiscal year 2023 was approximately HKD 2,523,000, compared to a profit of HKD 701,000 in fiscal year 2022[54]. Assets and Liabilities - The group's net assets increased by 2.3% to HKD 430.5 million, up from HKD 420.8 million in the previous year[5]. - The group's total assets less current liabilities stood at HKD 435.9 million, compared to HKD 421.5 million in fiscal year 2022[10]. - The total assets as of December 31, 2023, amounted to HKD 509,254,000, an increase from HKD 484,839,000 in 2022, reflecting a growth of approximately 5.0%[26]. - The total liabilities as of December 31, 2023, were HKD 78,789,000, up from HKD 63,990,000 in 2022, which is an increase of about 23.1%[26]. - As of December 31, 2023, the group's net current assets amounted to approximately HKD 250,127,000, an increase from HKD 246,217,000 in the fiscal year 2022[67]. - The group had cash and cash equivalents of approximately HKD 81,075,000 as of December 31, 2023, compared to HKD 60,069,000 in the fiscal year 2022, reflecting a significant increase[67]. Earnings Per Share - The group's basic and diluted earnings per share for fiscal year 2023 were HKD 0.15, compared to a loss of HKD 0.06 per share in the previous year[7]. - Basic and diluted earnings per share for 2023 were HKD 0.00149, compared to a loss per share of HKD 0.0006 in 2022[40]. Dividends - The board of directors did not recommend a final dividend for the fiscal year 2023, consistent with the previous year[5]. - The company did not declare or recommend any dividends for 2023, consistent with 2022[39]. - No dividends were proposed for the fiscal year 2023, consistent with the previous fiscal year[90]. Segment Performance - The company reported a segment loss of HKD 24,016,000 in the longevity science business for the year ended December 31, 2023, compared to a profit of HKD 8,953,000 in 2022[22][24]. - The longevity science segment generated revenue of approximately HKD 31,326,000, down from HKD 43,920,000 in fiscal year 2022, with a segment loss of HKD 24,016,000[57]. - The lending and financial consulting segment recorded revenue of approximately HKD 33,663,000, a decrease from HKD 45,748,000 in fiscal year 2022, with a segment profit of HKD 25,354,000[61]. Cash Flow and Financial Costs - The group's cash and cash equivalents increased to HKD 81.1 million in fiscal year 2023, up from HKD 60.1 million in the previous year[10]. - The company's financial cost for the year ended December 31, 2023, was HKD (1,936,000), compared to HKD (417,000) in 2022, indicating an increase in financial costs[22][24]. Compliance and Governance - The audit committee, consisting of three independent non-executive directors, has reviewed and approved the consolidated financial statements for the fiscal year 2023, ensuring compliance with applicable accounting standards and regulations[97]. - The company has adopted the standard code of conduct for securities trading by directors, confirming compliance throughout the year[96]. - The company is committed to enhancing its internal control systems to prevent future delays in financial reporting as per listing rules[93]. - The risk management committee has monitored the company's adherence to risk management and internal control guidelines[94]. - The chairman of the board, Yan Li, confirmed the board's commitment to overseeing the effectiveness of risk management and internal control systems[101]. Future Plans and Strategies - The company aims to achieve global leadership in the sales revenue of lipid-lowering biological products by 2024, with the competitive product ZJ1 VC being used in over 117 countries[47]. - The company plans to replicate its standardized longevity management services in 26 major cities globally, enhancing its brand image among high-net-worth individuals[49]. - The company plans to continue expanding its longevity science business and may consider forming joint ventures with strategic partners to maximize shareholder returns[83]. - A joint venture agreement was signed on February 26, 2024, to establish a company in China focused on the trade of biopharmaceutical products, with the group holding a 51% stake[88].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Zhong Ji Longevity Science Group Limited 中 基 長 壽 科 學 集 團 有 限 公 司 （於百慕達註冊成立之有限公司） （股份代號：767） 有關二零二二年全年╱二零二三年中期業績及 報告之澄清及補充公告 茲提述中基長壽科學集團有限公司（「本公司」）日期為二零二三年四月十九日之截至 二零二二年十二月三十一日止年度之全年業績公告（「二零二二年全年業績公告」）； 本公司於二零二三年四月二十八日刊發之截至二零二二年十二月三十一日止年度之 年報（「二零二二年年報」）；本公司日期為二零二三年八月二十三日之截至二零二三 年六月三十日止六個月之中期業績公告（「二零二三年中期業績公告」）及本公司於二 零二三年九月二十二日刊發之截至二零二三年六月三十日止六個月之中期報告（「二 零二三年中期報告」）。除另有說明外，本公告所用詞彙與二零二二年全年業績公告 及二零二二年年報以及二零二 ...

Dividend and Financial Performance - The Company did not declare an interim dividend for the six months ended 30 June 2023, consistent with the previous year[10]. - For the six months ended June 30, 2023, the Group recorded total revenue of HK$29,911,000, a decrease from HK$33,054,000 in the same period of 2022[36]. - The Group reported a profit for the period of HK$1,938,000, down from HK$6,437,000 in the prior year[36]. - The basic and diluted earnings per share were HK$0.01, compared to HK$0.04 in the same period of 2022[37]. - Profit for the period was HK$1,938,000, down 69.9% from HK$6,437,000 in the prior year[39]. - The Company reported revenue of HK$29,911,000, a decrease of approximately 9.5% compared to HK$33,054,000 for the same period in 2022[169]. - Gross profit for the same period was HK$26,487,000, down from HK$29,108,000, reflecting a decline of about 9.0%[169]. - Profit before tax for the period was HK$5,312,000, a decrease of approximately 13.7% from HK$6,152,000 in the prior year[169]. - The profit for the period attributable to owners of the Company was HK$1,782,000, down from HK$6,273,000, representing a decline of approximately 71.6%[169]. - The Company incurred selling and distribution expenses of HK$11,959,000, significantly higher than HK$1,258,000 in the previous year, indicating an increase of approximately 848.5%[169]. - Administrative expenses rose to HK$26,937,000 from HK$21,467,000, marking an increase of about 25.4%[169]. - Other comprehensive loss for the period totaled HK$80,621,000, compared to HK$28,721,000 in the previous year, reflecting a significant increase[171]. - Total comprehensive loss for the period attributable to owners of the Company was HK$77,226,000, up from HK$21,825,000 year-over-year[171]. Business Operations and Revenue Sources - The existing Money Lending & Financial Advisory Business has shown steady recovery growth despite challenges from COVID-19 restrictions in major cities[16]. - The Company operates its money lending business through two models: the "Strategic Partners Model" and the "Corporate and Personal Borrowers Model"[12]. - The Company’s strategic partners include China Foreign Economy and Trade Trust Co. Ltd, Shenzhen Fanhua Joint Investment Group Co. Ltd, and Chongqing Haier[12]. - The Company’s loan assets are primarily in the form of residential loans managed through strategic partners, with a focus on home mortgage products[17]. - The Company’s financial advisory business continues to adapt to the evolving market conditions post-P2P loan transition[16]. - The Group's principal activities include longevity science, money lending, financial advisory, securities investments, and property investment[187]. - The longevity science business is expected to become a key revenue growth driver for the Group, supported by a network of 2,000 pharmacy outlets across various regions in China[53]. - The Group's financial performance reflects a significant shift in revenue sources, particularly in diagnostic services[199]. Longevity Science Business - The Company is focused on expanding its longevity science business alongside its financial services[11]. - The Longevity Science Business contributed revenue of HK$11,868,000 but incurred a segment loss of HK$13,283,000[36]. - The longevity science business generated revenue of approximately HK$11,868,000, a decline of 33.9% from HK$17,953,000 in the same period last year, with a segmental loss of approximately HK$13,283,000 compared to a profit of HK$6,989,000 in 2022[42][44]. - Revenue from diagnostic consultation and medical testing was approximately HK$9,517,000, up 190.5% from HK$3,273,000 in the prior year[42][44]. - Sales of longevity biological products fell to approximately HK$2,351,000, a decrease of 84.0% from HK$14,680,000 in the same period last year due to customs clearance delays[43][45]. - The Group's strategy includes diversifying into the longevity medical health business, offering various advanced medical tests and treatments[27]. - The Group has strengthened its R&D capabilities by appointing Nobel laureate Randy Wayne Schekman as Honorary Chairman and Chief Scientist[47][49]. - The Group is developing its flagship NMN product "ZJ1" and other longevity biological products in California, with the R&D progress of "ZJ1" reaching the seventh generation[48][50]. - The Group plans to establish the "Internet + Healthcare" longevity system platform, Zhong Ji Longevity Cloud, leveraging its existing customer base and sales channels[48][50]. Market Environment and Challenges - The Company faces uncertainties due to PRC government policies offering mortgage repayment relief, impacting recovery actions[18]. - The Company’s operations are affected by the stringent market environment, particularly in property transactions in both PRC and Hong Kong[16]. - The PRC property market faced a slump, impacting the performance of home loans and secured loans in the Money Lending and Financial Advisory Business[34]. - The Group engaged a PRC law firm to expedite recovery actions on overdue loans, with progress reported by the end of July 2023[23]. Assets and Financial Position - The Group's consolidated net assets as of June 30, 2023, were HK$419,251,000, slightly down from HK$420,849,000 at the end of 2022[37]. - The Group's net asset value as of June 30, 2023, was HK$419,251,000, slightly down from HK$420,849,000 as of December 31, 2022[40]. - As of June 30, 2023, the Group recorded net current assets of approximately HK$231,394,000, a decrease from HK$246,217,000 as of December 31, 2022[85]. - The Group's cash and bank balances were approximately HK$58,733,000 as of June 30, 2023, down from HK$60,069,000 as of December 31, 2022[85]. - The total number of issued ordinary shares increased to 4,554,412,915 as of June 30, 2023, compared to 4,257,112,915 as of December 31, 2022[86]. - The gearing ratio of the Group was approximately 2.1% as of June 30, 2023, down from 2.4% as of December 31, 2022[105]. - The Group did not have any capital commitment as of June 30, 2023, consistent with the position as of December 31, 2022[107]. - The Group has not implemented any foreign currency hedging policy but is continuously monitoring foreign exchange exposure due to fluctuations in Renminbi[106]. - The Group had no material contingent liability as of June 30, 2023, the same as December 31, 2022[108]. Shareholding and Corporate Governance - The company continues to monitor and comply with the relevant regulations regarding shareholdings and interests[119]. - The total number of shares held by Mr. Yan Li, including convertible notes, represents approximately 212.79% of the total issued shares as of June 30, 2023[117][118]. - The company had no disclosed interests or short positions from directors or chief executives as of June 30, 2023[119][122]. - The company recorded no significant changes in substantial shareholders' interests as of June 30, 2023[120][123]. - The Company has complied with the Corporate Governance Code during the six months ended June 30, 2023[156]. Legal Matters - An unlawful leasehold interest transfer was discovered, involving Keen State Global Saipan, which was executed without the knowledge or authority of the Group[76]. - Internal inquiries confirmed that no staff or directors of the Group authorized the unlawful lease assignment, which is being challenged legally[79]. - The Group has authorized legal actions to invalidate the forged lease assignment and recover possession of the leasehold interest[81].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而 產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Zhong Ji Longevity Science Group Limited 中 基 長 壽 科 學 集 團 有 限 公 司 （於百慕達註冊成立之有限公司） （股份代號：767） 截至二零二三年六月三十日止六個月 留意人名： 中期業績公告 中基長壽科學集團有限公司（「本公司」）董事（「董事」）會（「董事會」）欣然宣佈本公司及其 曹衆女士係要用「衆」 附屬公司（統稱「本集團」）截至二零二三年六月三十日止六個月之未經審核簡明綜合中期 業績連同二零二二年同期之比較數字如下： 不是「眾」 ...

Financial Performance - In 2022, the company reported revenue of HK$89,668,000, an increase of 46.7% from HK$61,119,000 in 2021[10] - The company experienced a loss attributable to owners of HK$904,000 in 2022, compared to a profit of HK$6,055,000 in 2021[10] - As of December 31, 2022, total shareholders' equity was HK$420,849,000, down from HK$470,718,000 in 2021, representing a decrease of 10.5%[13] - The basic and diluted loss per share was approximately HK$0.01, a decrease from earnings per share of HK$0.04 in 2021[53][56] - For the year ended December 31, 2022, the Group recorded total revenue of approximately HK$89,668,000, an increase of 46.7% from HK$61,119,000 in 2021[52][55] - The longevity science business contributed revenue of approximately HK$43,920,000, up 96.0% from HK$22,446,000 in 2021, with a segment profit of approximately HK$8,953,000, compared to HK$3,500,000 in the previous year[58][61] - The Money Lending and Financial Advisory Business generated static revenue of approximately HK$45,748,000, with a segment profit of approximately HK$30,913,000[52][55] - For the year ended December 31, 2022, the money lending segment recorded revenue of approximately HK$45,748,000, up from HK$38,660,000 in 2021, and a profit of approximately HK$30,913,000, compared to HK$26,872,000 in 2021[72][74] Business Development - The company developed four longevity biological products in the US, all receiving the highest global standard of certification[16] - Strategic sales partnerships were formed with Sinopharm Group, Naber Pharmacy, Hong Kong Mannings Pharmacy, and Wing Wah Pharmacy[16] - The company has established a layout of Research & Development and production in the US, with services in Hong Kong and Japan, and marketing clients in China[16] - The company aims to build a membership-based international longevity management organization, providing advanced medical services in Hong Kong, Shenzhen, Los Angeles, and Tokyo[23] - The company is focused on optimizing its industrial and product chains to ensure healthy and sustainable development, despite ongoing economic uncertainties[21][24] - The Group's longevity science business is focusing on strengthening in-house R&D and production capabilities, including the appointment of Nobel laureate Randy Wayne Schekman as Honorary Chairman and Chief Scientist[60][62] - The Group has commenced the development and production of its flagship NMN product "ZJ1" and other longevity biological products in California, USA[64] - The Group aims to establish the "Internet + Healthcare" longevity system platform — Zhong Ji Longevity Cloud[64] Challenges and Regulatory Issues - The company faced trading suspension from January to late July 2022 due to regulatory challenges[14] - In 2022, the company faced challenges including the suspension of share trading from January to late July and the impact of the COVID-19 pandemic, yet it maintained a focus on steady progress and development[17] - The company successfully appealed to the Listing Review Committee in July 2022, leading to the resumption of share trading, which is expected to provide a fair development environment for sustainable growth[17][27] Corporate Governance and Management - The company aims to enhance corporate governance and business operations for sustainable development[14] - The company plans to continue enhancing its corporate governance and operational standards to protect shareholder interests and ensure sustainable growth[24] - The board includes independent non-executive directors with extensive experience in finance, corporate management, and medical fields[149][150][151][152] - The company’s governance structure includes multiple committees to oversee audit, remuneration, risk management, and nominations[149][150][151][152] - The Group is committed to enhancing its environmental, social, and governance (ESG) practices, with a report expected to be published by the end of April 2023[167] Strategic Partnerships - The company has established a strategic collaboration with Thermo Fisher Scientific, valued at over HK$20,000 billion, to enhance its longevity management services targeting high net worth individuals[19] - The company has established a strategic partnership with Stanford University's Center for Translational Medicine to develop advanced medical services in Hong Kong[19] - The Group has established a strategic partnership with Thermo Fisher Scientific, which will provide the latest life science technology and solutions to enhance the Group's R&D capabilities in longevity science[65][68] Investment and Financial Position - As of December 31, 2022, the consolidated net assets of the Group were approximately HK$420,849,000, down from HK$470,718,000 in 2021[53][56] - The Group recorded a net fair value loss of approximately HK$11,366,000 on listed securities investments, compared to a loss of HK$10,795,000 in 2021[81] - The Group's investment in 271,345,000 shares of Imperial Pacific International Holdings Limited amounted to an investment cost of approximately HK$76,490,000, representing about 3.8% of Imperial Pacific's issued share capital[82] - The fair value of the shares of Imperial Pacific held by the Group was HK$24,145,000 as of December 31, 2022, which accounted for 46.2% of the Group's total investment in listed securities and approximately 4.7% of the Group's total assets[82] - The Group commenced property investment business in 2021, but the properties remained vacant and did not generate any revenue in 2022 due to the pandemic[88] - The Group incurred miscellaneous expenses related to the properties during 2022 and plans to find suitable tenants or dispose of the properties for capital appreciation[88] Management Team - Mr. Yan Li has over 8 years of experience in advanced medical and biological technology management[133] - Mr. Yan Yifan joined the company as CEO in April 2022, previously serving as general manager of Mailyard Health Group[134] - Mr. Li Xiaoshuang, an executive director, has extensive experience in business operation and corporate management after retiring from gymnastics[138] - Ms. Cao Xie Qiong, an executive director, has a background in advanced biomedical technology and has held leadership roles in the food and beverage industry[139] - Dr. He Yiwu, a non-executive director, has a PhD from Boston University and extensive experience in innovation and pharmaceutical sectors[143] - Mr. Lyu Changsheng, an independent non-executive director, has over 20 years of experience in investment consulting and corporate development[144] - Mr. Lee See Barry, an independent non-executive director, has over 30 years of experience in audit, accounting, and financial management[145]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而 產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Zhong Ji Longevity Science Group Limited 中 基 長 壽 科 學 集 團 有 限 公 司 （於百慕達註冊成立之有限公司） （股份代號：767） 截至二零二二年十二月三十一日止年度 經審核全年業績公告 及 恢復買賣 中基長壽科學集團有限公司（「本公司」）董事（「董事」）會（「董事會」）欣然宣佈本公司及其 附屬公司（統稱「本集團」）截至二零二二年十二月三十一日止年度之綜合業績連同前一年 之比較數字。全年業績已由本公司審核委員會（「審核委員會」）審閱。 財務摘要 • 本集團收益增加46.8%至89.7百萬港元（二零二一年：61.1百萬港元）。 ...

Financial Performance - The Group recorded total revenue of HK$33,054,000 for the six months ended 30 June 2022, a significant increase from HK$16,112,000 in the same period of 2021, representing a growth of approximately 105%[43]. - The Group achieved a profit of HK$6,437,000 for the period, compared to a loss of HK$20,851,000 in the prior year, marking a turnaround in financial performance[43]. - The basic and diluted earnings per share improved to HK$0.04 cents, compared to a loss per share of HK$0.14 cents in the previous year[44]. - The Group's consolidated net assets decreased to HK$448,434,000 as of 30 June 2022, down from HK$470,718,000 at the end of 2021[44]. - The money lending and financial advisory business generated segment revenue of approximately HK$15,101,000, up from HK$8,941,000 in the previous year, with segment profit increasing to HK$12,684,000 from HK$244,000[56]. - The Group reported a net fair value loss of approximately HK$13,414,000 on listed securities investments during the review period, compared to a net fair value gain of HK$23,853,000 in the same period last year[72]. Business Development and Strategy - The management discussion highlighted a focus on expanding product offerings and enhancing user engagement metrics[16]. - The company is actively pursuing new product development initiatives aimed at improving market competitiveness[16]. - Future outlook indicates a commitment to market expansion and potential mergers and acquisitions to drive growth[16]. - The company is exploring strategic partnerships to enhance its technological capabilities[16]. - The Group is actively identifying acquisition opportunities to enhance its industry chain in longevity science[108]. - The Group plans to establish longevity medical testing centers in 18 first and second-tier cities in China over the next three years through mergers and acquisitions and strategic cooperation[147][148]. Risk Management and Governance - The company has established a risk management committee to better navigate market uncertainties[14]. - The board of directors underwent changes, with new appointments aimed at strengthening governance and oversight[14]. - The Group's operations are primarily exposed to risks including exchange rate risk, policy risk, credit risk, and liquidity risk[163]. - The slowdown of the PRC's economic growth and tightening financial regulations may adversely affect the Group's money lending and financial advisory businesses[164]. Longevity Science Business - The longevity science business contributed HK$17,953,000 in revenue and HK$6,989,000 in segment profit, which helped cushion the overall performance of the Group[43]. - The longevity science business has established two state-of-the-art testing centers in Hong Kong, offering advanced medical tests and genetic assessments[26]. - The Company aims to expand its longevity memberships and services targeting high-net-worth individuals in PRC, Hong Kong, and Southeast Asia[31]. - The Group's two patents for early cancer screening have been approved, significantly improving the effectiveness and accuracy of cancer prevention technologies[116]. - The Group is developing the "Internet + Healthcare" longevity system platform, Zhong Ji Longevity Cloud, leveraging existing customer bases and sales channels[131]. Research and Development - The Group plans to enhance its R&D capabilities by recruiting a seasoned team, including a Nobel laureate, to support its longevity science initiatives[101]. - The R&D focus will include the development of cell and gene therapy, along with providing cell testing, banking, and therapy services[158][159]. - The scientific research team has advanced the NMN product "ZJ1" to its seventh generation, introducing longevity functional beverages to improve health and longevity[131]. - The Group aims to build a world-class R&D team and facilities to accelerate innovation in longevity biological products[108]. Market Presence and Sales - The Group has formed a sales and distribution network with over 2,000 pharmacies in PRC to sell its longevity products since June 2022[31]. - The sales of longevity biological products contributed approximately HK$14,680,000 to the revenue of the longevity science segment for the six months ended June 30, 2022[99]. - The Group anticipates achieving aggregate sales of approximately RMB 109 million across over 2,000 pharmacy outlets from now until December 2024 through China GuoYao's sales and distribution contracts[158][159]. - The Group has launched an overseas flagship store on Tmall Global for the sale of ZJ1 series nutritional supplements, which includes ZJ1 NMN multi-series longevity supplements and ZJ1 VC tablets[137]. Shareholding and Capital Structure - The total number of issued ordinary shares as of June 30, 2022, remained at 3,870,102,650, unchanged from December 31, 2021[166]. - As of June 30, 2022, Mr. Yan Li held 498,855,175 shares and a 90.76% shareholding interest in Zhong Ji 1 International Medical Group, which holds convertible notes worth HK$1,840,000,000, convertible into 9,200,000,000 shares of the Company[192]. - Mr. Li Xiaoshuang held 38,680,000 share options, entitling him to subscribe for an equivalent number of shares[192]. - The Group did not pledge any assets to banks or other financial institutions as of June 30, 2022[171].

Financial Performance - Revenue for the year ended December 31, 2021, was HK$61,119,000, a decrease of 23.6% from HK$80,022,000 in 2020[6] - Profit attributable to the owners of the Company for 2021 was HK$61,119,000, compared to a loss of HK$11,487,000 in 2020[6] - The Company declared dividends of HK$6,055,000 for 2021, recovering from a loss of HK$11,487,000 in the previous year[6] - Total revenue for 2019 was HK$145,846,000, indicating a significant decline over the past two years[6] - For the year ended December 31, 2021, the Group's revenue was HK$61,119,000, a decrease from HK$80,022,000 in 2020[12] - The Group achieved a profit for the year of HK$51,909,000, compared to a loss of HK$72,458,000 in 2020, marking a significant turnaround[12] - The net profit for the year was HK$6,200,000, a recovery from a loss of HK$10,700,000 in 2020[12] - Total comprehensive income for the year was HK$15,832,000, a year-on-year increase of 33.37 times from a loss of HK$512,555,000 in 2020[12] - Adjusted EBITDA for the reporting year was approximately HK$29,010,000, slightly down from HK$29,549,000 in 2020[72] - The Money Lending business segment recorded revenue of approximately HK$27,218,000, down from HK$61,154,000 in 2020, with no interest income recorded for the year[86][87] - The financial and investment advisory business segment generated revenue of approximately HK$11,442,000, a decrease from HK$13,151,000 in 2020, due to COVID-19 related restrictions[88] Business Strategy and Outlook - The Company is focusing on expanding its market presence and enhancing product offerings in the longevity science sector[5] - Future outlook includes potential new product launches and technological advancements in longevity science[5] - The management is committed to improving operational efficiency and exploring strategic partnerships for growth[5] - The Company aims to recover from previous losses and return to profitability in the upcoming fiscal periods[5] - Ongoing research and development efforts are expected to drive innovation and market competitiveness[5] - The Group plans to implement a "supply chain finance + longevity science" dual-drive model for sustainable development[36][40] - The Group aims to develop financial services for the health product supply chain, targeting an estimated annual income of about HK$40 million from the milk powder industry chain[44] - The Group's strategic transformation includes dividing the lending finance business into corporate lending and mortgage loans in a strategic cooperation mode[42][45] - The Group is committed to risk control in its lending business while actively introducing longevity science as a new business to sustain healthy development[64] - The Group's long-term strategy includes transitioning from P2P lending to a focus on longevity science and healthcare solutions in the Greater China region[70] Financial Position - Total net assets for the Group increased to HK$470,718,000, representing a year-on-year growth of 3.48%[18] - Net current assets rose to HK$232,256,000, reflecting an increase of 48.76% over 2020[18] - The fair value of total financial assets for the year was HK$1,121,667,000[18] - As of December 31, 2021, the Group recorded net current assets of approximately HK$232,256,000, an increase from HK$156,120,000 in 2020[110] - The Group's cash and cash equivalents were approximately HK$19,437,000, down from HK$40,797,000 in 2020[110] - The gearing ratio of the Group as of December 31, 2021, was approximately 1.6%, unchanged from 2020[120] Operational Developments - The Group's transformation strategy included a shift from P2P lending to new money lending and financing consultation services in response to regulatory changes[11] - The Group had 3,291 money lending customers and realized an operating revenue of HK$38,660,000 from the money lending and loan interest segment in 2021[43][45] - The Group's impaired loans totaled HK$980,912,000, with a special debt settlement team established to manage collections under regulatory policies[48] - The Group's property investment business has not generated any revenue as the properties remain vacant due to their recent acquisition and the pandemic[105] - The Group will continue to monitor market conditions to find suitable tenants for its properties or consider disposing of them for capital appreciation[108] Research and Development - The Group's cancer early screening technology has obtained FDA certification for breast, prostate, and rectal cancer, with plans for domestic clinical testing this year and aims to achieve medical device certification within 1.5 to 3 years[53] - The Group's longevity biologics products received FDA certification and are currently sold in approximately 2,000 pharmacies in China, with plans to expand to 5,000 pharmacies in the next three years[58] - The longevity science business is divided into three segments: cancer prevention and early screening, longevity medical examination services, and R&D of longevity biological products, targeting high net worth individuals[49] - The Group's longevity medical health business includes advanced tumor cell screening and various health tests, contributing to its diversified revenue streams[70] Governance and Management - The board of directors includes independent non-executive directors with extensive experience in finance and management, enhancing corporate governance[144][146][148] - The Company has engaged an external service provider as company secretary to ensure compliance and governance standards[151] - The honorary chairman, Academician Randy Wayne Schekman, is a Nobel Prize laureate, adding significant scientific credibility to the company[150][152] - The management team includes individuals with diverse backgrounds in business, healthcare, and technology, enhancing the Company's strategic capabilities[136] - The Company emphasizes the importance of risk management and compliance through its various committees[144][147] Shareholder and Financial Policies - The Company aims to explore ways to improve financial performance and diversify operations into more profitable businesses[113] - The Company will consider its financial performance, earnings, and liquidity requirements when deciding on any future dividend payouts[171] - The Company did not recommend the payment of any dividend for the year ended December 31, 2021, consistent with 2020[125] - The Company has complied with relevant laws and regulations, including the Money Lenders Ordinance and the Hong Kong Companies Ordinance, for the year ended December 31, 2021[168] Changes in Board and Management - Mr. Yan Li has over 8 years of experience in advanced medical and biological technology management, and founded HK Zhong Ji 1 in 2014, which focuses on knee joint health resources[131] - Mr. Yan Yifan joined the Company as CEO in April 2022, previously serving as general manager of Mailyard Health Group since April 2021[132] - Mr. Li Xiaoshuang, an executive director since August 2021, has extensive experience in business operation and corporate management after retiring from a successful gymnastics career[136] - Mr. Wang Hongxin resigned as an executive director and ceased to act as CEO on December 8, 2021[185] - Mr. Li Jiuhua was appointed as an executive director and CEO on December 8, 2021, and resigned on April 8, 2022[185] - The Company has undergone several changes in its Board of Directors, with multiple resignations and appointments in 2021[178]

Financial Performance - The Group recorded total revenue of HK$16,112,000 for the six months ended 30 June 2021, a decrease of 23.5% compared to HK$20,956,000 for the same period in 2020 [26]. - The Group incurred a loss of HK$20,851,000 during the period, compared to a profit of HK$16,039,000 in the previous year, marking a significant downturn in financial performance [26]. - The basic and diluted loss per share was HK$0.54 cents, compared to earnings per share of HK$0.41 cents and HK$0.11 cents in the same period last year [27]. - The Group recorded net current assets of approximately HK$120,516,000 as of June 30, 2021, down from HK$156,120,000 at the end of 2020 [152]. - Cash and bank balances were approximately HK$20,300,000 as of June 30, 2021, compared to HK$40,797,000 at the end of 2020 [152]. Business Operations - The company is focusing on expanding its longevity science business, alongside its existing operations in money lending, securities, and property investment [13]. - The company aims to capture the growth potential of the longevity science industry through business diversification [13]. - The longevity science business generated revenue of HK$7.2 million and a net profit of HK$2.84 million, providing a cushion against overall losses [26]. - The Group's property investment business has not yet generated any revenue as all properties acquired during the review period remain vacant [81]. - The Group is in the process of renewing its money lenders license, which is crucial for continuing its lending operations [39]. Investment and Acquisitions - The Group acquired two examination centers in January 2021, enhancing its longevity medical testing capabilities with 19 categories of testing platforms [107]. - A memorandum of understanding was signed to acquire Asian Integrated Cell Laboratory Limited, a major FDA-registered international auto-immune cell bank, to advance cell therapies and pharmaceuticals [108]. - The Group acquired Banderland Development for RMB 154 million, which holds a 55% equity interest in Hangzhou Chengnan Hospital, enhancing its medical service capabilities [120]. - The Group plans to establish longevity medical testing centers in 18 first and second-tier cities in China over the next three years through mergers and acquisitions [146]. Research and Development - The Group appointed Nobel laureate Randy Wayne Schekman as Honorary Chairman and Chief Scientist to enhance its R&D capabilities [94]. - The scientific research team advanced the R&D of "ZJ1" to the seventh generation, introducing longevity functional beverages to promote health and longevity [122]. - The patents for the Group's early cancer screening inventions have been approved, enhancing its position in cancer prevention and early screening [107]. - The Group's two cancer early screening patents have been approved, significantly improving the effectiveness and accuracy of cancer screening [109]. - A strategic partnership was formed with Thermo Fisher Scientific to enhance the Group's R&D capabilities in longevity science and medical diagnostics [130]. Market Outlook - The longevity science industry is projected to flourish, with increasing public awareness of health and longevity post-COVID-19 pandemic [133]. - The longevity supplement market in China is projected to reach RMB 27 billion by 2023, growing at nearly 70% year-on-year [147]. - The management is confident in the business performance for the second half of the year, expecting the longevity science business to drive revenue growth [132]. Challenges and Risks - The money lending business did not generate any interest income during the period, a decline from HK$536,000 in the same period of 2020 [39]. - The Group has engaged legal advisors to pursue outstanding loans and interest receivables, indicating ongoing challenges in loan recovery [41]. - The segment profit for the same period was approximately HK$4,220,000, down from HK$19,102,000 in the previous year, attributed to a decrease in outstanding loans and interest receivables [43]. - The Group has not recognized any impairment provision for the six months ended June 30, 2021, compared to HK$120,000 for the same period in 2020 [43]. Corporate Governance - The Group's total number of issued ordinary shares remained at 3,870,102,650 as of June 30, 2021 [152]. - The Group did not have any capital commitments as of June 30, 2021, consistent with December 31, 2020 [193][194]. - There were no material contingent liabilities reported as of June 30, 2021, similar to the situation on December 31, 2020 [193][194]. - The Group has not implemented any foreign currency hedging policy but continuously monitors foreign exchange exposure due to fluctuations in Renminbi [190][192]. Shareholding Structure - Mr. Yan Li holds 9,200,000,000 shares in long position, representing 237.72% of the total shares as of June 30, 2021 [198]. - The beneficial ownership of Mr. Yan Li is 184,030,000 shares in long position, accounting for 4.76% of the total shares [198]. - Ms. Cao Xie Qiong holds 41,540,000 shares in long position, which is 1.07% of the total shares [198]. - As of June 30, 2021, no other directors or chief executives had interests or short positions in any shares or debentures of the company [199].